Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.

Urologic oncology - 1 Dec 2016

Sweis Randy F, Galsky Matthew D

Abstract excerpt

Urothelial bladder cancer is one of the first cancers recognized to be immunogenic since 40 years ago when the use of bacillus Calmette-Guerin was shown to prevent recurrence. Since that time, our knowledge of immune biology of cancer has expanded tremendously, and patients with bladder cancer finally have new active immunotherapeutic drugs on the horizon. Anti-programmed cell death-1 (PD-1)/programmed cell death...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Antigen-Presenting Cells
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Carcinoma, Transitional Cell

Share to Lymphocytes, Tumor-Infiltrating

Share to Programmed Cell Death 1 Receptor

Share to Tumor Escape

Source

Open in PubMed Open full text

Identifiers

PMID: 27836246
DOI: 10.1016/j.urolonc.2016.10.006
PMCID: PMC5709811

Genes

UBC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.PMID 27836246Read ↗

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Semantic proximity Read ↗

Identification of tumor antigens and immune subtypes of bladder cancer for mRNA vaccine developmentSemantic proximity Read ↗

Identification of Four Immune Subtypes in Bladder Cancer Based on Immune Gene SetsSemantic proximity Read ↗

Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer.Semantic proximity Read ↗

Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.Semantic proximity Read ↗

Bladder Cancer: A Review.Semantic proximity Read ↗

Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.Semantic proximity Read ↗

Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancerSemantic proximity Read ↗

Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: Based on TCGA Database and BioinformaticsSemantic proximity Read ↗

Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.Semantic proximity Read ↗

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer.Semantic proximity Read ↗

PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.